Page last updated: 2024-10-20

pteridines and Triple Negative Breast Neoplasms

pteridines has been researched along with Triple Negative Breast Neoplasms in 2 studies

Triple Negative Breast Neoplasms: Breast neoplasms that do not express ESTROGEN RECEPTORS; PROGESTERONE RECEPTORS; and do not overexpress the NEU RECEPTOR/HER-2 PROTO-ONCOGENE PROTEIN.

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (50.00)24.3611
2020's1 (50.00)2.80

Authors

AuthorsStudies
Nieto-Jimenez, C1
Galan-Moya, EM1
Corrales-Sanchez, V1
Noblejas-Lopez, MDM1
Burgos, M1
Domingo, B1
Montero, JC1
Gomez-Juarez, M1
Picazo-Martinez, MG1
Esparis-Ogando, A1
Pandiella, A1
OcaƱa, A1
Davies, AH1
Reipas, K1
Hu, K1
Berns, R1
Firmino, N1
Stratford, AL1
Dunn, SE1

Other Studies

2 other studies available for pteridines and Triple Negative Breast Neoplasms

ArticleYear
Inhibition of the mitotic kinase PLK1 overcomes therapeutic resistance to BET inhibitors in triple negative breast cancer.
    Cancer letters, 2020, 10-28, Volume: 491

    Topics: Animals; Azepines; Cell Cycle Proteins; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; G2 Phas

2020
Inhibition of RSK with the novel small-molecule inhibitor LJI308 overcomes chemoresistance by eliminating cancer stem cells.
    Oncotarget, 2015, Aug-21, Volume: 6, Issue:24

    Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Female; Humans; Neoplast

2015